Drak2 is not required for tumor surveillance and suppression

Benjamin A. Edwards, Tarsha L. Harris, Helen Floersh, John R. Lukens, Md Hasan Zaki, Peter Vogel, Thirumala Devi Kanneganti, Jack D. Bui, Maureen A. McGargill

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2-/- mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.

Original languageEnglish (US)
Pages (from-to)161-166
Number of pages6
JournalInternational Immunology
Issue number3
StatePublished - Mar 2015


  • Autoimmunity
  • Regulation of immune responses
  • Tumor surveillance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Drak2 is not required for tumor surveillance and suppression'. Together they form a unique fingerprint.

Cite this